Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Halozyme Therapeutics Incorporated HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

GlobeNewswire January 5, 2026

Jim Lang Elected to Halozyme's Board of Directors

PR Newswire December 8, 2025

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

PR Newswire December 4, 2025

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

PR Newswire November 25, 2025

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

PR Newswire November 18, 2025

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

PR Newswire November 17, 2025

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

PR Newswire November 7, 2025

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

PR Newswire November 6, 2025

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

PR Newswire November 5, 2025

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

PR Newswire November 3, 2025

Halozyme to Report Third Quarter 2025 Financial and Operating Results

PR Newswire October 21, 2025

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

PR Newswire October 1, 2025

Halozyme to Participate at Upcoming Investor Conferences

PR Newswire August 28, 2025

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

PR Newswire August 5, 2025

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

PR Newswire July 23, 2025

Halozyme to Report Second Quarter 2025 Financial and Operating Results

PR Newswire July 22, 2025

Halozyme Therapeutics Added to Russell 1000® Index

PR Newswire June 30, 2025

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PR Newswire June 20, 2025

Halozyme to Participate at Upcoming Investor Conferences

PR Newswire May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

PR Newswire May 28, 2025

Podcasts